Gilead Sciences (GILD) Stock Sinks As Market Gains: What You Should Know

Gilead Sciences stock declined 1.87% to $144.74 while broader markets gained, underperforming the S&P 500's 0.73% rise. The HIV and hepatitis C drugmaker has lost 2.46% over the past month, with the Medical sector down 3.74%. Upcoming earnings are projected at $2.15 per share (down 12.96% year-over-year) with revenue expected at $7.79 billion (up 0.3%). The stock holds a Zacks Rank #3 (Hold) rating.